Eikon Therapeutics, Inc. 8-K

What Happened
Eikon Therapeutics, Inc. (EIKN) filed an 8‑K on March 30, 2026 (Item 2.02) to announce clinical and corporate updates and to report its financial results for the three months and the full year ended December 31, 2025. The company furnished a press release dated March 30, 2026 as Exhibit 99.1, which is incorporated by reference in the filing.

Key Details

• Date of announcement: March 30, 2026.
• Reporting period: three months and full year ended December 31, 2025 (Q4 2025 and FY 2025 results reported).
• Document furnished: Press release dated March 30, 2026 included as Exhibit 99.1; Interactive XBRL cover page included (Exhibit 104).
• SEC items cited: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).

Why It Matters
This 8‑K signals that the company has published its latest earnings and provided operational/clinical updates investors should review. The press release will contain the specific financial figures (revenue, net income/loss, cash balance/runway, and any guidance) and any clinical progress or corporate changes that could affect near‑term catalysts and valuation. Retail investors should read the Exhibit 99.1 press release and subsequent filings for the detailed numbers and context before making investment decisions.